诚意药业(603811.SH)：前三季度净利润1.43亿元，同比增长21.91%

Core Viewpoint - Chengyi Pharmaceutical (603811.SH) reported a revenue of 597 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 14.69% [1] - The net profit attributable to shareholders reached 143 million yuan, marking a year-on-year increase of 21.91% [1] - The basic earnings per share stood at 0.45 yuan [1] Financial Performance - Total operating revenue for the first three quarters was 597 million yuan, up 14.69% compared to the previous year [1] - Net profit attributable to the parent company was 143 million yuan, representing a 21.91% increase year-on-year [1] - Basic earnings per share recorded at 0.45 yuan [1]